UNIGE document Scientific Article
previous document  unige:85275  next document
add to browser collection

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

Puttini, Miriam
Coluccia, Addolorata Maria Luce
Boschelli, Frank
Cleris, Loredana
Marchesi, Edoardo
Donella-Deana, Arianna
Redaelli, Sara
show hidden authors show all authors [1 - 14]
Published in Cancer Research. 2006, vol. 66, no. 23, p. 11314-11322
Abstract Resistance to imatinib represents an important scientific and clinical issue in chronic myelogenous leukemia. In the present study, the effects of the novel inhibitor SKI-606 on various models of resistance to imatinib were studied. SKI-606 proved to be an active inhibitor of Bcr-Abl in several chronic myelogenous leukemia cell lines and transfectants, with IC(50) values in the low nanomolar range, 1 to 2 logs lower than those obtained with imatinib. Cells expressing activated forms of KIT or platelet-derived growth factor receptor (PDGFR), two additional targets of imatinib, were unaffected by SKI-606, whereas activity was found against PIM2. SKI-606 retained activity in cells where resistance to imatinib was caused by BCR-ABL gene amplification and in three of four Bcr-Abl point mutants tested. In vivo experiments confirmed SKI-606 activity in models where resistance was not caused by mutations as well as in cells carrying the Y253F, E255K, and D276G mutations. Modeling considerations attribute the superior activity of SKI-606 to its ability to bind a conformation of Bcr-Abl different from imatinib.
Keywords Aniline Compounds/chemistry/pharmacologyAnimalsBenzamidesCell LineCell LineTumorCell Proliferation/drug effectsDasatinibDose-Response RelationshipDrugDrug ResistanceNeoplasm/drug effectsFusion ProteinsBcr-abl/genetics/metabolismGenotypeHumansImatinib MesylateK562 CellsMiceMiceNudeModelsMolecularMutation/geneticsNeoplasms/drug therapy/genetics/pathologyNitriles/chemistry/pharmacologyPiperazines/pharmacologyProtein Kinase Inhibitors/chemistry/pharmacologyPyrimidines/pharmacologyQuinolines/chemistry/pharmacologySurvival AnalysisThiazoles/pharmacologyU937 CellsXenograft Model Antitumor Assays/methodsSrc-Family Kinases/antagonists & inhibitors/metabolism
PMID: 17114238
Full text
Article (Published version) (451 Kb) - document accessible for UNIGE members only Limited access to UNIGE
(ISO format)
PUTTINI, Miriam et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. In: Cancer research, 2006, vol. 66, n° 23, p. 11314-11322. doi: 10.1158/0008-5472.CAN-06-1199 https://archive-ouverte.unige.ch/unige:85275

379 hits

1 download


Deposited on : 2016-07-14

Export document
Format :
Citation style :